Berger Financial Group Inc Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Berger Financial Group Inc raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,544 shares of the company's stock after acquiring an additional 803 shares during the period. Berger Financial Group Inc's holdings in Eli Lilly and Company were worth $5,052,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Gerber Kawasaki Wealth & Investment Management lifted its stake in shares of Eli Lilly and Company by 216.8% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 6,522 shares of the company's stock valued at $5,035,000 after acquiring an additional 4,463 shares during the period. Rinkey Investments bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $205,000. Prosperity Consulting Group LLC lifted its position in shares of Eli Lilly and Company by 15.7% in the fourth quarter. Prosperity Consulting Group LLC now owns 9,653 shares of the company's stock worth $7,452,000 after purchasing an additional 1,308 shares in the last quarter. Bolthouse Investments LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $540,000. Finally, Boothbay Fund Management LLC lifted its position in shares of Eli Lilly and Company by 135.3% in the fourth quarter. Boothbay Fund Management LLC now owns 5,457 shares of the company's stock worth $4,213,000 after purchasing an additional 3,138 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 10.0 %

LLY traded down $89.48 during trading on Thursday, reaching $809.47. 8,693,608 shares of the stock traded hands, compared to its average volume of 3,804,592. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $767.52 billion, a PE ratio of 69.00, a P/E/G ratio of 1.40 and a beta of 0.51. The stock's 50-day moving average is $828.65 and its 200 day moving average is $817.92. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's revenue was up 45.2% compared to the same quarter last year. During the same period last year, the company posted $2.58 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,000.32.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.